

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAPplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 18 CA/CAPplus to be enhanced with pre-1967 CAS Registry Numbers

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:02:11 ON 21 JUN 2007

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:02:20 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1
DICTIONARY FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10581829\10581829b.str



chain nodes :

16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

4-10 13-16

ring bonds :

1-2 1-8 2-3 2-9 3-4 4-5 5-6 6-7 6-9 7-8 10-11 10-15 11-12 12-13 13-14
14-15

exact/norm bonds :

1-2 1-8 2-3 2-9 3-4 4-5 5-6 6-7 6-9 7-8 13-16

exact bonds :

4-10

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1

STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss

SAMPLE SEARCH INITIATED 14:03:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2125 TO ITERATE

94.1% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 39735 TO 45265

PROJECTED ANSWERS: 1182 TO 2302

L2 50 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 14:03:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42642 TO ITERATE

100.0% PROCESSED 42642 ITERATIONS

1597 ANSWERS

SEARCH TIME: 00.00.01

L3 1597 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 14:03:38 ON 21 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jun 2007 VOL 146 ISS 26

FILE LAST UPDATED: 20 Jun 2007 (20070620/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 15 L3


=> d l4 1-15 ibib abs hitstr

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:768921 CAPLUS
 DOCUMENT NUMBER: 145:188915
 TITLE: 7-[4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide as inhibitors of renin for the treatment of hypertension
 INVENTOR(S): Bezencon, Olivier; Bur, Daniel; Fischli, Walter; Remen, Lubos; Richard-Bildstein, Sylvia; Sifferlen, Thierry; Weller, Thomas
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
 SOURCE: PCT Int. Appl., 26pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006079988	A1	20060803	WO 2006-1850285	20060126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		WO 2005-EP842	A 20050128


PRIORITY APPLN. INFO.:
 GI

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The invention relates to a novel 3,9-diazabicyclo[3.3.1]nonene derivative I, and the enantiomers thereof, and the use thereof as active ingredients in the preparation of pharmaceutical compns. A multistep preparation of I is described as well as resolution of the racemate to provide II. In renin inhibition assays, II displayed IC50 value of 0.3 nM. The invention also concerns related aspects including pharmaceutical compns. containing at least one compound of formula I or II and especially their use as inhibitors of renin.
 IT 903579-35-1P
 RI: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of
 [(dichloromethylphenoxy)ethoxy]phenyl)diazabicyclo[3.3.1]nonene-6-carboxylic acid cyclopropyl(dimethylbenzyl)amide as inhibitors of renin for the treatment of hypertension)
 RN 903579-35-1 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl]-N-[(2,3-dimethylphenyl)methyl]-(9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 903579-36-2P
 RI: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of
 [(dichloromethylphenoxy)ethoxy]phenyl)diazabicyclo[3.3.1]nonene-6-carboxylic acid cyclopropyl(dimethylbenzyl)amide as inhibitors of renin for the treatment of hypertension)
 RN 903579-36-2 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl]-N-[(2,3-dimethylphenyl)methyl]-(1R,5S)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:60620 CAPLUS
 DOCUMENT NUMBER: 145:62930
 TITLE: Heteroaryl-substituted azabicyclononene derivatives as renin inhibitors, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Bezencon, Olivier; Boss, Christoph; Bur, Daniel; Corinne, Olivier; Fischli, Walter; Grisostomi, Corinne; Remen, Lubos; Richard-Bildstein, Sylvia; Sifferlen, Thierry; Weller, Thomas
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064484	A1	20060622	WO 2005-1854276	20051215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		WO 2004-EP14401	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		WO 2004-EP14401	A 20041217

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 145:62930
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to heteroaryl-substituted azabicyclononene derivs. I, which are renin inhibitors. In compds. I, X is (un)substituted N, O, or S; V is -L1-Z-L2-, where L1 is -OCH2- or -CH2CH2-, L2 is a bond, O, or CH2, and Z is 5-membered heteroaryl rings containing 2 or 3 heteroatoms

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
independently selected from N, O, and S; U is (un)substituted phenyl; R1 is C1-7 alkyl or C3-6 cycloalkyl; and R2 is (un)substituted phenyl; including stereoisomers, racemates, salts, solvates and morphol. forms thereof. The invention also relates to the prepn. of I, pharmaceutical compns. contg. a compd. according to formula I and a pharmaceutically acceptable carrier material, as well as to the use of the compns. for the treatment of cardiovascular events and renal insufficiency.

Metal-halogen exchange of (4-bromophenoxy)triisopropylsilane followed by substitution of triflate II, demethylation, N-Boc-protection, and ester hydrolysis gave the carboxylic acid, which was amidated with N-cyclopropyl-2,3-dichlorobenzylamine and desilylated to give phenol III. Condensation of 2-chloro-3,6-difluorobenzaldehyde with hydroxylamine followed by heterocyclization with 3-(tert-butylidimethylsilyloxy)propyne and desilylation gave [3-(2-chloro-3,6-difluorophenyl)isoxazol-5-yl]methanol, which underwent coupling with phenol III and deprotection, resulting in the formation of IV. Compd. IV expresses an IC50 value of 0.8 nM in an assay for inhibition of human recombinant renin.

IT 890934-57-3P, (1R,5S)-7-[4-[[3-(2-Chloro-3,6-difluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(chiral intermediate; preparation of azabicyclononene derivs. as renin inhibitors)
RN 890934-57-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-3,6-difluorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 890846-78-3P, 7-[4-[[5-(2-Chloro-3,6-difluorophenyl)-(1,2,4)oxadiazol-3-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)
890846-79-4P, 7-[4-[[5-(2-Chlorophenyl)-(1,2,4)oxadiazol-3-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(3-methoxy-2-methylbenzyl) 890846-80-7P, 7-[4-[[3-(2,3-Dichlorophenyl)-(1,2,4)oxadiazol-5-yl]ethyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(3-methoxy-2-methylbenzyl) 890846-81-8P, 7-[4-[[2-[3-(2,6-Dichlorophenyl)-


L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
890934-74-4P, 7-[4-[[3-(3-Chloro-6-fluoro-2-trifluoromethylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-75-5P, 7-[4-[[3-(2,6-

Dimethylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
890934-76-6P, 7-[4-[[3-(2,5-Dichlorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of azabicyclononene derivs. as renin inhibitors)
RN 890846-78-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[5-(2-chloro-3,6-difluorophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890846-79-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[5-(2-chlorophenyl)-(1,2,4-oxadiazol-3-yl]methoxy]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890846-80-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-[3-(2,3-dichlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
[1,2,4]oxadiazol-5-yl]ethyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)
890846-82-9P, 7-[4-[[3-(2-Chloro-3,6-difluorophenyl)-(1,2,4)oxadiazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-54-0P, 7-[4-[[2-(2-Chloro-3,6-difluorophenyl)isoxazol-4-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-55-1P, 7-[4-[[3-(2-Chloro-3,6-

difluorophenyl)isoxazol-3-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-56-2P, (1R,5S)-3-Acetyl-7-[4-[[3-(2-chloro-3,6-

difluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
890934-58-4P, 7-[4-[[3-(4-Fluoro-2-trifluoromethylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-59-5P, 7-[4-[[3-(2-Chloro-6-fluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-60-8P, 7-[4-[[3-(2,5-


Difluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
890934-61-9P, 7-[4-[[3-(2-Chloro-4-fluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-62-0P, 7-[4-[[3-(5-Chloro-1,3-dimethyl-1H-pyrazol-4-yl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-63-1P, 7-[4-[[3-(2,4-Dichlorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-64-2P, 7-[4-[[3-(2,6-

Dichlorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
890934-65-3P, 7-[4-[[3-(2,3,6-Trichlorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-66-4P, 7-[4-[[3-(2-Fluoro-6-trifluoromethylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-67-5P, 7-[4-[[3-(2,3-


Dichlorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)
890934-68-6P, 7-[4-[[3-(2-Chloro-6-fluoro-3-methylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-69-7P, 7-[4-[[3-(3-Chloro-2-fluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-70-0P, 7-[4-[[3-(6-Chloro-2-fluoro-3-methylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-71-1P, 7-[4-[[3-(3-Chloro-2-fluoro-6-trifluoromethylphenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl) 890934-73-3P, 7-[4-[[3-(3-Chloro-2,6-

difluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-(2,3-dichlorobenzyl)


L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 890846-81-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-[3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890846-82-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-3,6-difluorophenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890934-54-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[2-[3-(2-chloro-3,6-difluorophenyl)-4-oxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-55-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[5-(2-chloro-3,6-difluorophenyl)-3-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-56-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-[[3-(2-chloro-3,6-difluorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 890934-58-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-isoxazolyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 890934-59-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-60-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[3-(2,5-difluorophenyl)-5-isoxazolyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 890934-61-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-4-fluorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-62-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-5-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-63-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[3-(2,4-dichlorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-64-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[3-(2,6-dichlorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-65-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[3-(2,3,6-trichlorophenyl)-5-isoxazolyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 890934-66-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[3-(2-fluoro-6-(trifluoromethyl)phenyl)-5-isoxazolyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 890934-67-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[[4-[(2,3-dichlorophenyl)methyl]-5-isoxazolyl]methoxy]phenyl]-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-68-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(2-chloro-6-fluoro-3-methylphenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-69-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(3-chloro-2-fluorophenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-74-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-75-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[[4-[(3-(2,6-dimethylphenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-76-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[[4-[(3-(2,5-dichlorophenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-70-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(6-chloro-2-fluoro-3-methylphenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890934-71-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(3-chloro-2-fluoro-6-(trifluoromethyl)phenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890934-73-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(3-chloro-2,6-difluorophenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



IT 890846-83-0P, 7-[[4-[(3-(2-chloro-3,6-difluorophenyl)isoxazol-5-yl)methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(racemic drug candidate; preparation of azabicyclononene derivs. as renin inhibitors)

RN 890846-83-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[[4-[(3-(2-chloro-3,6-difluorophenyl)-5-isoxazolyl)methoxy]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:606519 CAPLUS
DOCUMENT NUMBER: 145:83392
TITLE: Heteroaryl-substituted diazabicyclononene derivatives
as renin inhibitors, their preparation,
pharmaceutical
compositions, and use in therapy
INVENTOR(S): Bezencon, Olivier; Remen, Lubos; Sifferlen, Thierry;
Grisostomi, Corinna; Richard-Bildstein, Sylvia; Bur,
Daniel; Boss, Christoph; Corninboeuf, Olivier;
Fischli, Walter; Weller, Thomas
PATENT ASSIGNEE(S): Actellon Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063610	A1	20060622	WO 2004-EPI4401	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
ZW	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HM, HR, HS, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
WO 2006064484	A1	20060622	WO 2005-IB54276	20051215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HM, HR, HS, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
PRIORITY APPLN. INFO.:			WO 2004-EPI4401	A 20041217


OTHER SOURCE(S): MARPAT 145:83392
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to heteroaryl-substituted diazabicyclononene
derivs.
I, which are renin inhibitors. In compds. I, V is -L1-L2-L2-, where L1 is
-OCH2- or -CH2CH2-, L2 is a bond, -O-, or -CH2-, and Z is 5-membered

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 890846-79-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide,
7-[4-[[5-(2-chlorophenyl)-
1,2,4-oxadiazol-3-yl]methoxy]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-
methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890846-80-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[2-[3-
(2,3-dichlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]phenyl]-N-[(3-methoxy-2-
methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890846-81-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[2-[3-
(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl]ethyl]phenyl]-N-[(3-methoxy-2-
methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 890846-82-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-3,6-
difluorophenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-
methylphenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
heteroarylene congt. 2 or 3 heteroatoms; U is (un)substituted phenyl; R1
is Cl-7 alkyl or C3-6 cycloalkyl; and R2 is (un)substituted phenyl;
including stereoisomers, racemates, salts, solvates and morphol. forms
thereof. The invention also relates to the prepn. of I, pharmaceutical
compsns. contg. at least one compd. according to formula I and
pharmaceutically acceptable carrier materials or adjuvants, as well as to
the use of the compns. for the treatment of cardiovascular events and
renal insufficiency. Metal-halogen exchange of (4-
bromophenoxy)triisopropylsilane followed by substitution of triflate II,
demethylation, N-Boc-protection, and ester hydrolysis gave the carboxylic
acid, which was amidated with N-cyclopropyl-2,3-dichlorobenzylamine and
desilylated to give phenol III. Condensation of 2-chloro-3,6-
difluorobenzaldehyde with hydroxylamine followed by heterocyclization
with
3-(tert-butylidimethylsilyloxy)propyne and desilylation gave
[3-(2-chloro-3,6-difluorophenyl)isoxazol-5-yl]methanol, which underwent
coupling with phenol III and ester cleavage, resulting in the formation
of
IV. Compd. IV expresses an IC50 value of 0.8 nM in an assay for
inhibition of human recombinant renin.

IT 890846-78-3P, 7-[4-[[5-(2-Chloro-3,6-difluorophenyl)-
[1,2,4]oxadiazol-3-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-
carboxamide N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)-
890846-79-4P, 7-[4-[[5-(2-Chlorophenyl)-[1,2,4]oxadiazol-3-
yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide
N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)-890846-80-7P,
7-[4-[2-[3-(2,3-Dichlorophenyl)-[1,2,4]oxadiazol-5-yl]ethyl]phenyl]-3,9-
diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-[(3-methoxy-2-
methylphenyl)-890846-81-8P, 7-[4-[2-[3-(2,6-Dichlorophenyl)-
[1,2,4]oxadiazol-5-yl]ethyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-
carboxamide N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)-
890846-82-9P, 7-[4-[[3-(2-Chloro-3,6-difluorophenyl)-
[1,2,4]oxadiazol-5-yl]methoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-
carboxamide N-cyclopropyl-N-[(2,3-dichlorobenzyl)-890846-83-OP,
7-[4-[[3-(2-Chloro-3,6-difluorophenyl)isoxazol-5-yl]methoxy]phenyl]-3,9-
diazabicyclo[3.3.1]non-6-ene-6-carboxamide N-cyclopropyl-N-[(2,3-
dichlorobenzyl)-
RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of diazabicyclononene derivs. as renin
inhibitors)


RN 890846-78-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[5-(2-chloro-3,6-
difluorophenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-N-cyclopropyl-N-[(3-
methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 890846-83-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-3,6-
difluorophenyl)-5-isoxazolyl]methoxy]phenyl]-N-cyclopropyl-N-[(2,3-
dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:578204 CAPLUS

DOCUMENT NUMBER: 145:46095

TITLE: Diazabicyclononene derivatives as renin inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Bezencon, Olivier; Bur, Daniel; Fischli, Walter; Remen, Lubos; Richard-Bildstein, Sylvia; Sifferlen, Thierry; Weber, Hans-Peter; Weller, Thomas

PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006061791	A2	20060613	WO 2005-1B54113	20051208
WO 2006061791	A3	20060810		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: WO 2004-EP13949 A 20041208

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to diazabicyclononene derivative I, the racemate as well as the individual enantiomers thereof, which are renin inhibitors. The invention also relates to the preparation of I, pharmaceutical compns. containing compound I and a pharmaceutically acceptable carrier material, as well as to the use of the compns. for the treatment of cardiovascular events and renal insufficiency. Preparation of Grignard reagent from 1,4-dibromobenzene followed by substitution of allyl bromide, hydroboration, oxidation, and protection with tert-butyltrimethylsilyl chloride gave bromide II. O-Trifluoromethanesulfonylation of III followed by substitution with lithiated II, demethylation, desilylation, N-protection, and coupling with 2-chloro-3,6-difluorophenol gave ether IV, which underwent ester hydrolysis, amidation with N-cyclopropyl-2,3-dichlorobenzylamine, deprotection, and chiral HPLC to give (1R,5S)-diazabicyclononene I. Compound (1R,5S)-I expresses an IC50 value of 0.5 nM in an assay for

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

inhibition of human recombinant renin.

IT 889881-63-4P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

renin (chiral drug candidate; preparation of diazabicyclononene derivs. as inhibitors)

RN 889881-63-4 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 889881-62-3P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

renin (racemic drug candidate; preparation of diazabicyclononene derivs. as inhibitors)

RN 889881-62-3 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:542922 CAPLUS

DOCUMENT NUMBER: 145:28021

TITLE: Bicyclic lactam derivatives as renin inhibitors, their

preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Bezencon, Olivier; Boss, Christoph; Bur, Daniel; Corminboeuf, Olivier; Fischli, Walter; Grisostomi, Corinna; Remen, Lubos; Richard-Bildstein, Sylvia; Sifferlen, Thierry; Weller, Thomas

PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006059304	A2	20060608	WO 2005-1B54008	20051201
WO 2006059304	A3	20061012		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006058546	A1	20060608	WO 2004-EP13610	20041201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: WO 2004-EP13610 A 20041201


OTHER SOURCE(S): MARPAT 145:28021

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to bicyclic lactam deriva. of formula I, which are renin inhibitors. In compds. I, W is 1,4-disubstituted phenylene; V is oxyalkyl, alkoxy, or oxyalkoxy; U is (un)substituted phenyl; T is -C(O)N(R1)-, where R1 is alkyl or cycloalkyl; Q is alkylene; M is

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(un)substituted Ph or (un)substituted pyridinyl; and J is H or lower alkyl; including stereoisomers, solvates, polymorphs, and salts thereof. The invention also relates to the prepn. of I, pharmaceutical compns. contg. at least one compd. I and a pharmaceutically acceptable carrier material, as well as to the use of the compns. for the treatment of cardiovascular events and renal insufficiency. N-Protection of DL-allylglycine followed by amidation with N-methylglycinate, cyclizative deprotection, carboxylation, and hydride redn. gave piperazine II, which was cyclized, oxidized, and carboxylated, resulting in the formation of bicyclic compd. III. O-Trifluoromethanesulfonylation of III followed by substitution with lithiated 4-[3-(tert-butylidimethylsilyloxy)propyl]phenyl bromide, desilylation, and coupling with 2-chloro-3,6-difluorophenol gave ether IV, which underwent ester cleavage, amidation with N-cyclopropyl-2,3-dichlorobenzylamine, and carbamate removal to give bicyclic lactam V. Compd. V expresses IC50 value below 10 nM in an assay for inhibition of human recombinant renin.
IT 889128-15-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic lactam derivs. as renin inhibitors)
RN 889128-15-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
alkylene; M is (un)substituted phenyl; and J is H or lower alkyl; including stereoisomers, solvates, polymorphs, and salts thereof. The invention also relates to the prepn. of I, pharmaceutical compns. contg. at least one compd. I and pharmaceutically acceptable carrier materials or adjuvants, as well as to the use of the compns. for the treatment of cardiovascular events and renal insufficiency. N-Protection of DL-allylglycine followed by amidation with N-methylglycinate, cyclizative deprotection, carboxylation, and hydride redn. gave piperazine II, which was cyclized, oxidized, and carboxylated, resulting in the formation of bicyclic compd. III. O-Trifluoromethanesulfonylation of III followed by substitution with lithiated 4-[3-(tert-butylidimethylsilyloxy)propyl]phenyl bromide, desilylation, and coupling with 2-chloro-3,6-difluorophenol gave ether IV, which underwent ester cleavage, amidation with N-cyclopropyl-2,3-dichlorobenzylamine, and carbamate removal to give bicyclic lactam V. Compd. V expresses IC50 value of 2.1 nM in an assay for inhibition of human recombinant renin.
IT 889128-15-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic lactam derivs. as renin inhibitors)
RN 889128-15-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-3-methyl-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:542920 CAPLUS
DOCUMENT NUMBER: 145:28020
TITLE: Bicyclic lactam derivatives as renin inhibitors, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Bezencon, Olivier; Remen, Lubos; Sifferlen, Thierry; Grisostomi, Corinna; Richard-Bildstein, Sylvia; Bur, Daniel; Boss, Christoph; Corminboeuf, Olivier; Fischli, Walter; Weller, Thomas
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058546	A1	20060608	WO 2004-EP13610	20041201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MG, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006059304	A2	20060608	WO 2005-IB54008	20051201
WO 2006059304	A3	20061012		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: WO 2004-EP13610 A 20041201

OTHER SOURCE(S): MARPAT 145:28020
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to bicyclic lactam derivs. of formula I, which are renin inhibitors. In compds. I, W is 1,4-disubstituted phenylene; V is oxy-lower alkyl, lower alkoxy, or oxy-lower alkoxy; U is (un)substituted aryl; T is -C(O)N(R1)-, where R1 is lower alkyl or cycloalkyl; Q is lower

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:333438 CAPLUS
DOCUMENT NUMBER: 144:350717
TITLE: Preparation of bicyclononene derivatives as inhibitors of renin
INVENTOR(S): Bezencon, Olivier; Boss, Christoph; Bur, Daniel; Corminboeuf, Olivier; Fischli, Walter; Grisostomi, Corinna; Remen, Lubos; Richard, Sylvia; Sifferlen, Thierry; Weller, Thomas
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021399	A2	20060302	WO 2005-EP9045	20050822
WO 2006021399	A3	20061026		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: WO 2004-EP9475 A 20040825

OTHER SOURCE(S): MARPAT 144:350717
GI



AB The invention relates to novel bicyclic compounds. (I) [wherein X = NH, N(L), CH₂, CH(L), O, S; W = Ph substituted by V in para-position; V = CH₂N(R)CH₂, CH₂N(R)CH₂CH₂, CH₂CH₂N(R), N(R)CH₂CH₂, OCH₂CH₂N(R), CH₂CH₂N(R)CH₂, CH₂CH₂N(R)CH₂CH₂, CH₂N(R)CH₂CH₂O, CH₂CH₂CH₂N(R), N(R)CH₂CH₂CH₂O, or CH₂CH₂N(R)CO; U = (un)substituted Ph, quinolinyl; T = CONR₁; Q = methylene; M = each (un)substituted Ph or pyridinyl; L = R₃, COR₃, CO₂R₃, CONR₂R₃, SO₂R₃, SO₂NR₂R₃; wherein R = H, alkyl, cycloalkyl, CH₂CF₃; R₁ = alkyl, cycloalkyl; R₂ = H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl; R₃ = each (un)substituted alkyl, cycloalkyl, or cycloalkylalkyl and optically pure enantiomers, mixts. of enantiomers such as racemates, diastereomers, mixts. of diastereomers, diastereomeric racemates, mixts. of diastereomeric racemates, and meso-forms, as well as salts and solvent complexes of such compds., and morphol. forms. The these compds. are renin inhibitors and are useful for the treatment or prophylaxis of diseases selected from hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intraocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other diseases known to be related to the renin-angiotensin system. Thus, 2-chloro-3,6-difluorobenzaldehyde underwent reductive amination with 6-(cyclopropyl(3-methoxy-2-methylbenzyl)carbamoyl)-7-[4-(2-methylaminoethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-3,9-dicarboxylic acid

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-methylbenzyl)amide 881849-38-8P, 7-[4-[(2-[(2-chloro-6-fluoro-3-methylbenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-34-9P, 7-[4-[(2-[(2-chloro-3,6-difluorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-35-0P, 7-[4-[(2-[(2-chloro-6-fluorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-36-1P, 7-[4-[(2-[(2,3-dichlorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-37-2P, 7-[4-[(2-[(2-chlorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-39-4P, 7-[4-[(2-[(2,6-dichlorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-40-7P, 7-[4-[(2-[(2,4-dimethylphenyl)oxy]ethyl)-N-methylamino]ethyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-41-8P, 7-[4-[(2-[(2,6-dichloro-4-methylbenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-42-9P, 7-[4-[(2-[(2-chlorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-43-0P, 7-[4-[(2-[(2,3,6-trichlorobenzyl)ethyl]amino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-44-1P, 7-[4-[(2-[(2-chlorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-45-2P, 7-[4-[(2-[(2,6-dimethylbenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-46-3P, 7-[4-[(2-[(2-methyl-N-(2,3,6-trichlorobenzyl)amino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-47-4P, 7-[4-[(2-[(2-methyl-N-(2,3,6-trichlorobenzyl)amino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-48-5P, 7-[4-[(2-[(2-chloro-2,6-difluorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-49-6P, 7-[4-[(2-[(2-chlorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-50-9P, 7-[4-[(2-[(2,3,5-trifluorobenzyl)amino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-51-0P, 7-[4-[(2-[(2,3,6-trifluorobenzyl)amino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-52-1P, 7-[4-[(2-[(2-chloro-3,6-difluorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-53-2P, 7-[4-[(2-[(2,2-difluorobenzodioxol-4-yl)methyl]-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-54-3P,

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
acid di-tert-Bu ester followed by treatment with 4 M HCl/dioxane in CH₂Cl₂ to give 7-[4-[(2-[(2-chloro-3,6-difluorobenzyl)methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide (II). II showed IC₅₀ of 2.4 nM against recombinant human renin.
IT 881849-16-7P, 7-[4-[(3-[(N-(2,4-difluorophenyl)-N-methylamino]propyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-17-8P, 7-[4-[(3-[(N-methyl-N-phenylamino]propyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-18-9P, 7-[4-[(3-[(N-methyl-N-(m-tolyl)amino]propyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-19-0P, 7-[4-[(3-[(N-methyl-N-(o-tolyl)amino]propyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-20-3P, 7-[4-[(3-[(N-(2-chlorophenyl)-N-methylamino]propyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-21-4P, 7-[4-[(3-[(N-(3-chlorophenyl)-N-methylamino]propyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-22-5P, 7-[4-[(2-[(N-methyl-N-phenylamino]ethoxy)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-23-6P, 7-[4-[(2-[(N-(3-chloro-2,6-difluorobenzyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-24-7P, 7-[4-[(2-[(N-(4,5-dichloroisothiazol-3-yl)carbonyl)-N-methylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-25-8P, 7-[4-[(N-(2,4-dichlorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-26-9P
7-[4-[(N-(2-chloro-6-fluoro-3-methylbenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-27-0P, 7-[4-[(N-(2-chloro-3,6-difluorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-28-1P, 7-[4-[(N-(2-chloro-4-fluorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-29-2P, 7-[4-[(N-(2-chloro-6-fluorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-30-5P***, 7-[4-[(N-(2,3-dichlorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide ***881849-31-6P, 7-[4-[(N-(2-chlorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-32-7P, 7-[4-[(N-(2,6-dichlorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
7-[4-[(N-ethyl-N-(2,3,6-trichlorobenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-55-4P, 7-[4-[(N-(2-cyanobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-56-5P, 7-[4-[(N-(2,6-difluorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-57-6P, 7-[4-[(N-ethyl-N-(2,4,6-trifluorobenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-58-7P, 7-[4-[(N-(2-chloro-6-fluoro-3-methylbenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-59-8P, 7-[4-[(N-(2,4-dichlorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-60-1P, 7-[4-[(N-(2-chloro-6-fluorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-61-2P, 7-[4-[(N-ethyl-N-(2-fluoro-5-methoxybenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-62-3P, 7-[4-[(N-ethyl-N-(2-fluoro-6-trifluoromethylbenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-63-4P, 7-[4-[(N-(2,5-dichlorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-64-5P, 7-[4-[(N-(2,6-dimethylbenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-65-6P, 7-[4-[(N-(6-chloro-2-fluoro-3-methylbenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-66-7P, 7-[4-[(N-(2,3-difluorobenzyl)-N-methylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-67-8P
7-[4-[(2-[(N-(3-chloro-2,6-difluorobenzyl)-N-cyclopropylamino]ethyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-68-9P, 7-[4-[(N-(3-chloro-2-fluorobenzyl)-N-isopropylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-69-0P, 7-[4-[(N-(3-chloro-2,6-difluorobenzyl)-N-cyclopropylamino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-70-3P, 7-[4-[(N-cyclopropyl-N-(2,6-dichlorobenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-71-4P, 7-[4-[(N-cyclopropyl-N-(2,3-dichlorobenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-72-5P, 7-[4-[(N-cyclopropyl-N-(2,3,6-trichlorobenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-73-6P, 7-[4-[(N-cyclopropyl-N-(2,6-dimethylbenzyl)amino]methyl)phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STM (Continued)
 881849-74-7P, 7-[4-[[N-(2-Cyanobenzyl)-N-cyclopropylamino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide
 881849-75-8P, 7-[4-[[N-Cyclopropyl-N-[[quinolin-4-yl)methyl]amino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide
 881849-76-9P, 7-[4-[[N-(6-Chloro-2-fluoro-3-methylbenzyl)-N-cyclopropylamino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide
 881849-77-0P, 7-[4-[[N-Cyclopropyl-N-(2-fluoro-6-trifluoromethylbenzyl)amino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide
 881849-78-1P, 7-[4-[[N-(2-Fluoro-5-methylphenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-79-2P, 7-[4-[[N-(2,3-Dichlorophenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-80-5P, 7-[4-[[N-(2,6-


Difluorophenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-81-6P, 7-[4-[[N-(2,6-Dichlorophenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-82-7P, 7-[4-[[N-(2,5-Difluorophenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-83-8P, 7-[4-[[N-(5-Chloro-2-methylphenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-84-9P, 7-[4-[[N-(2,5-Dichlorophenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-85-0P, 7-[4-[[N-(3-Fluoro-2-methylphenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-86-1P, 7-[4-[[N-(5-Fluoro-2-methylphenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-87-2P, 7-[4-[[N-(2-Chloro-5-methylphenyl)-N-methylamino]propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)amide 881849-88-3P, 7-[4-[[N-(3-Chloro-2,6-difluorobenzyl)-N-(2,2,2-trifluoroethyl)amino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-89-4P, 7-[4-[[N-(3-Chloro-2-fluoro-6-trifluoromethylbenzyl)-N-(2,2,2-trifluoroethyl)amino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide 881849-90-7P, 7-[4-[[N-(3-Chloro-2-fluorobenzyl)-N-isopropylamino]methyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-(2,3-dichlorobenzyl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of bicyclonone derivs. as inhibitors of renin for prophylaxis or treatment of diseases related to the renin-angiotensin system)

RN 881849-16-7 CAPLUS


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STM (Continued)



RN 881849-20-3 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-[(2-chlorophenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-21-4 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-[(3-chlorophenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-22-5 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[2-(methylphenylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STM (Continued)
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[3-[(2,4-difluorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 881849-17-8 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[3-(methylphenylamino)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-18-9 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[3-(methyl(3-methylphenyl)amino)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-19-0 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[3-(methyl(2-methylphenyl)amino)propyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS ON STM (Continued)




RN 881849-23-6 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[2-[(3-chloro-2,6-difluorobenzyl)methylamino]ethyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-24-7 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-[[4,5-dichloro-3-isothiazolyl]carbonyl]methylamino]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-25-8 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-[[4,5-dichloro-3-isothiazolyl]carbonyl]methylamino]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-26-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(2-chloro-6-fluoro-3-methylphenyl)methyl]methylamino]methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-27-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(2-chloro-3,6-difluorophenyl)methyl]methylamino]methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-28-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(2-chloro-4-fluorophenyl)methyl]methylamino]methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-32-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[[(2,6-dichlorophenyl)methyl]methylamino]methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-33-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-[[[(2-chloro-6-fluoro-3-methylphenyl)methyl]methylamino]ethyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-34-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-[[[(2-chloro-3,6-difluorophenyl)methyl]methylamino]ethyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-29-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(2-chloro-6-fluorophenyl)methyl]methylamino]methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-30-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[[(2,3-dichlorophenyl)methyl]methylamino]methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-31-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(2-chlorophenyl)methyl]methylamino]methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-35-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-[[[(2-chloro-6-fluorophenyl)methyl]methylamino]ethyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-36-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[2-[[[(2,3-dichlorophenyl)methyl]methylamino]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-37-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-[[[(2-chlorophenyl)methyl]methylamino]ethyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-39-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-((2,6-dichlorophenyl)methyl)methylamino]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-40-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-(2,4-dimethylphenoxy)ethyl]methylamino]methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-41-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[[2,6-dichloro-4-methylphenyl)methyl]methylamino]methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-45-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[2-[[2,6-dimethylphenyl)methyl]methylamino]ethyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-46-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[2-[[methyl]-(2,3,6-trichlorophenyl)methyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-47-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[ethyl]-(2,3,5-trifluorophenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-42-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[2-chlorophenyl)methyl]cyclopropylamino]methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-43-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[methyl]-(2,3,6-trichlorophenyl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-44-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[2-[[3-chlorophenyl)methyl]methylamino]ethyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-48-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[3-chloro-2,6-difluorophenyl)methyl]ethylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-49-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[3-chlorophenyl)methyl]ethylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-50-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[ethyl]-(2,3,5-trifluorophenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 881849-51-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(ethyl(2,3,6-trifluorophenyl)methyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-52-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[(2-chloro-3,6-difluorophenyl)methyl]ethylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-53-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(2,2-difluoro-1,3-benzodioxol-4-yl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(2,6-difluorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-57-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(ethyl(2,4,6-trifluorophenyl)methyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-58-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[(2-chloro-6-fluoro-3-methylphenyl)methyl]ethylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-59-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(2,4-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 881849-54-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(ethyl(2,3,6-trichlorophenyl)methyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-55-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[(2-chloro-3,6-difluorophenyl)methyl]ethylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-56-5 CAPLUS


L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-60-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[(2-chloro-6-fluorophenyl)methyl]ethylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-61-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(ethyl(2-fluoro-5-methoxyphenyl)methyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-62-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(ethyl(2-fluoro-6-(trifluoromethyl)phenyl)methyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-63-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-64-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-65-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-69-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-70-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-71-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-66-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-67-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-68-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-72-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-73-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-74-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[[[(2,5-dichlorophenyl)methyl]ethylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 881849-75-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[cyclopropyl(4-quinolinylmethyl)amino]methyl]phenyl]-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-76-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(6-chloro-2-fluoro-3-methylphenyl)methyl]cyclopropylamino]methyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-80-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2,6-difluorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-81-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2,5-difluorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-82-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2,5-difluorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-77-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[cyclopropyl[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]amino]methyl]phenyl]-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-78-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2-fluoro-5-methylphenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-79-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2,3-dichlorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-83-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-[(5-chloro-2-methylphenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-84-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2,5-dichlorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-85-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[3-[(2,5-difluorophenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 881849-86-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(5-fluoro-2-methylphenyl)methylamino]propyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 881849-87-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(2-chloro-5-methylphenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 881849-88-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(3-chloro-2,6-difluorophenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2006:193834 CAPLUS
DOCUMENT NUMBER: 144:274301
TITLE: Preparation of diazabicyclononylacetamides as renin inhibitors.
INVENTOR(S): Bezencon, Olivier; Boss, Christoph; Bur, Daniel; Corminboeuf, Olivier; Fischli, Walter; Grisostomi, Corinna; Remen, Lubos; Richard, Sylvia; Sifferlen, Thierry; Weller, Thomas
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd, Switz.
SOURCE: PCT Int. Appl., 46 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021403	A1	20060302	WO 2005-EP9050	20050822

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2004-EP9474 A 20040825

OTHER SOURCE(S): MARPAT 144:274301
GI




AB Title compds. (I; Z = NH, NL, CH2, O, S; W = Ph substituted by V in para position; V = oxyalkylene, oxyalkyleneoxy; U = (substituted) aryl; X,


Y = bond, alkylene; Q = CONR1; M = (substituted) Ph, pyridyl; L = R3, COR3, CO2R3, CONR2R3, SO2NR2R3; R1 = alkyl, cycloalkyl; R2 = H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl; R3 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl; with a proviso), were prepared Thus,

racemic
N-(2-chlorobenzyl)-2-[(1R*,5S*,6R*)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-7-en-6-yl]-N-cyclopropylacetamide (multistep preparation given) inhibited renin with


IC50 = 1.4 nM.
IT 877995-55-6P 877995-56-7P 877995-57-8P
877995-58-9P 877995-60-3P 877995-62-5P



RN 881849-89-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(3-chloro-2-fluorophenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 881849-90-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[3-(3-chloro-2-fluorophenyl)methylamino]propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




877995-64-7P 877995-66-9P 877995-67-0P
877995-69-2P 877995-71-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of diazabicyclononylacetamides as renin inhibitors)
RN 877995-55-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-chlorophenyl)methyl]-N-cyclopropyl-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-56-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-fluoro-5-methoxyphenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-57-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-58-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-methoxy-3-methyl-4-pyridinyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-64-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2,3-dimethylphenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-66-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-methyl-N-(phenylmethyl)-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-60-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(3-methoxyphenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-62-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-67-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-[(2-chlorophenyl)methyl]-N-ethyl-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-69-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(3,5-dimethoxyphenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 877995-71-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(3,4-dimethoxyphenyl)methyl]-, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 877996-05-9P 877996-06-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazabicyclononenylacetamides as renin inhibitors)
RN 877996-05-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-, monohydrochloride, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 877996-06-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-7-ene-6-acetamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-methoxy-3-methyl-4-pyridinyl)methyl]-, monohydrochloride, (1R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:193413 CAPLUS
DOCUMENT NUMBER: 144:274299
TITLE: Preparation of diazabicyclononenes as renin inhibitors.
INVENTOR(S): Bezencon, Olivier; Bossa, Christoph; Bur, Daniel; Corminboeuf, Olivier; Fischli, Walter; Grisostomi, Corinna; Remen, Lubos; Richard, Sylvia; Sifferlen, Thierry; Weller, Thomas
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021401	A2	20060302	WO 2005-EP9048	20050822
WO 2006021401	A3	20060413		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2004-EP9476 A 20040825

OTHER SOURCE(S): CASREACT 144:274299; MARPAT 144:274299
GI




AB Title compds. [I: X = NH, NL, CH2, CHL, O, S; W = 1,4-phenylene; V = ElZE2; E1 = bond, CH2; E2 = O, CH2O; Z = pyrrolidinylene, azetidinylenes;
U = (substituted) aryl, 5-membered heteroaryl; T = CONR1; Q = CH2; M = (substituted) Ph, pyridyl; L = R3, COR3, CO2R3, CONR2R3, SO2R3, SO2NR2R3; R1 = alkyl, cycloalkyl; R2 = H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl; R3 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl; with a proviso], were prepared Thus,
(1R,5S)-7-[4-[(3R)-3-(2,6-dichloro-4-methylphenoxy)pyrrolidin-1-yl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl(3-methoxy-2-methylbenzyl)amide (multistep preparation given) inhibited renin with IC50 = 1.1 nM.
IT 878012-13-6P 878012-14-7P 878012-15-8P
878012-16-9P 878012-17-0P 878012-27-2P

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compd.; prepn. of diazabicyclononenes as renin inhibitors)
 RN 878012-13-6 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]-7-[4-[[[(3S)-3-(2,3,6-trifluorophenoxy)-1-pyrrolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 878012-14-7 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[[(3S)-3-(2,6-dichlorophenoxy)-1-pyrrolidinyl)methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878012-15-8 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[[(3S)-3-(2,6-dichloro-4-fluorophenoxy)-1-pyrrolidinyl)methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 878012-27-2 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[[[(3R)-3-(2,3-difluorophenoxy)-1-pyrrolidinyl)methyl]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 878013-39-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diazabicyclononenes as renin inhibitors)
 RN 878013-39-9 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(3S)-3-(2-chloro-6-

fluoro-3-methylphenoxy)-1-pyrrolidinyl)methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 878012-16-9 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(3S)-3-(2-chloro-3,6-difluorophenoxy)-1-pyrrolidinyl)methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 878012-17-0 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[[[(3R)-3-(2-chloro-6-fluoro-3-methylphenoxy)-1-pyrrolidinyl)methyl]phenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:523456 CAPLUS
 DOCUMENT NUMBER: 143:60005
 TITLE: Preparation of diazabicyclononene derivatives and their use as renin inhibitors
 INVENTOR(S): Bezencon, Olivier; Richard-Bildstein, Sylvia; Bur, Daniel; Fischli, Walter; Weller, Thomas; Remen, Lubos;
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054243	A1	20050616	WO 2004-EP13578	20041130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295091	A1	20050616	AU 2004-295091	20041130
CA 2547547	A1	20050616	CA 2004-2547547	20041130
EP 1692133	A1	20060823	EP 2004-819638	20041130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1890240	A	20070103	CN 2004-80035894	20041130
JP 2007513106	T	20070524	JP 2006-541864	20041130
US 2007111989	A1	20070517	US 2006-581829	20060602
IN 2006CN02464	A	20070608	IN 2006-CN2464	20060705
PRIORITY APPL. INFO.:			WO 2003-EP313767	A 20031205
			WO 2004-EP13578	W 20041130

OTHER SOURCE(S): MARPAT 143:60005
 GI




AB Novel 3,9-diazabicyclo[3.3.1]nonene derivs. of formula (I) [X, W = N, CH;

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 854053-00-2 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-methoxyethoxy)-2-methylphenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 V = (CH2)x, A-(CH2)s, CH2-A-(CH2)t, (CH2)s-A, (CH2)2-A-(CH2)u, A-(CH2)v-B,
 (CH2)3-A-CH2, A-CH2CH2-B-CH2, CH2-A-CH2CH2-B, (CH2)3-A-CH2-CH2, etc.; A,
 B
 = O, S, S(O), S(O)2; U = aryl, heteroaryl; T = CONR1, (CH2)pOCO, (CH2)pN(R1)CO, (CH2)pN(R1)SO2, CO2; Q = lower alkylene or alkenylene; M = aryl-O-(CH2)VR7, heteroaryl-O-(CH2)VR7, aryl-O-(CH2)VO(CH2)WR7, heteroaryl-(CH2)VO(CH2)WR7, etc.; L = R3, COR3, CO2R3, CONR2R3, SO2R3, SO2NR2R3, COCH(Aryl)2; R1 = H, lower alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, cycloalkyl-lower alkyl; R2, R2' = H, lower alkyl or alkenyl, cycloalkyl, cycloalkyl-lower alkyl; R3 = H, each (un)substituted lower alkyl or alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl-lower alkyl, aryl-lower alkyl, heteroaryl-lower alkyl, etc.;
 R5
 = OH, lower alkoxy, -OCOR2, CO2, NR2R2', OCONR2R2', NCONR2R2', cyano, CONR2R2', SO3H, SONR2R2', CO-morpholin-4-yl,
 CO-[(4-loweralkyl)piperazin-1-yl], -NH(NH)NH2, etc.; R6 = OH, OR2, OCOR2, OCOOR2; or R6 and R5 form together with the carbon atoms to which they are attached a (un)substituted 1,3-dioxolane ring; R7 = lower alkoxy; m, n, z = 0, 1;

P, t, v = 1-4; r = 3-6; s = 2-5; u = 1-3, w = 1,2 integer) and optically pure enantiomers, their mixts. pharmaceutically acceptable salts, solvent complexes, and morphol. forms. These compds. are renin inhibitors and useful for the treatment or prophylaxis of disorders which are assocd. with dysregulation of the renin-angiotensin system (RAS). The disorders include cardiovascular and renal diseases hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS. For example, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-[(2-methoxyethoxy)-3-methylpyridin-4-yl]methyl]amide and 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid N-cyclopropyl-N-[(2-methoxyethoxy)-2-methylbenzyl]amide showed IC50 of 1.00 and 1.05 nM, resp., against human recombinant renin.
 IT 854052-99-6P 854053-00-2P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diazabicyclononene derivs. as renin inhibitors for treatment or prophylaxis of disorders associated with dysregulation of renin-angiotensin system)
 RN 854052-99-6 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-methoxyethoxy)-3-methyl-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:395311 CAPLUS
 DOCUMENT NUMBER: 142:463754
 TITLE: Preparation of diazabicyclononene derivatives as inhibitors of renin
 INVENTOR(S): Bezencon, Olivier; Sifferlen, Thierry; Bur, Daniel; Fischli, Walter; Weller, Thomas; Remen, Lubos;
 Richard-Bildstein, Sylvia
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040165	A1	20050506	WO 2004-EP11186	20041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283821	A1	20050506	AU 2004-283821	20041007
CA 2540782	A1	20050506	CA 2004-2540782	20041007
EP 1678176	A1	20060712	EP 2004-790163	20041007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1867568	A	20061122	CN 2004-80029967	20041007
JP 2007508262	T	20070405	JP 2006-530110	20041007
IN 2006CN01640	A	20070608	IN 2006-CN1640	20060511
PRIORITY APPL. INFO.:			WO 2003-EP11316	A 20031013
			WO 2003-EP311316	A 20031013
			WO 2004-EP11186	W 20041007

OTHER SOURCE(S): MARPAT 142:463754
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X and W independently = N, -CH-; V = -A, -CH2-CH2-CH2-A-CH2-CH2-, -CH2-CH2-CH2-A-CH2-, etc.; A = O, S, -SO-, etc.; U = aryl, heteroaryl; T = -CONR1, -COO-, -(CH2)pN(R1)CO-, etc.; R1 = H, alkyl, alkenyl, etc.; Q = alkylene, alkenylene; M = aryl-O-(CH2)qR2, heteroaryl-O-(CH2)qR2, aryl-O-(CH2)2O(CH2)qR2, etc.; p = 1-4; R2 = OH, CN, SO3H, etc.; L = -(CH2)mN(R1)(CH2)m-x; X1 = R3, COR3, COOR3, etc.; R3 = H, cycloalkyl, aryl, etc.; q = 2-4; y = 1-2; n and m = 0-1; x = 0-1 with provisions] and their pharmaceutically acceptable salts, are prepared and

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
disclosed as renin inhibitors. Thus, e.g., II was prep'd. by amidation of 2-chloroisonicotinoyl chloride with aniline followed by a methylation/redn. sequence to give intermediate 2-chloro-3-methylpyridine-4-carbaldehyde (III). III underwent reductive amination with cyclopropylamine followed by substitution with 3-(tert-butylidimethylsilyloxy)propan-1-ol to provide the desired pyridinylmethylamine intermediate which was used to couple with (rac.)-(1R,5S)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-3,6,9-tricarboxylic acid 3,9-di-tert-Bu ester (prepn. given). The coupling product was subjected to deprotection to provide II. The activity of I was evaluated in in vitro inhibition assays of human recombinant renin and it revealed that all compds. of the invention possessed IC50 values in the range of 0.49 up to 1.43 nM. I as inhibitors of renin should prove useful in the treatment of diseases such as, but not limited to, hypertension, congestive heart failure and pulmonary hypertension. Pharmaceutical compns. comprising of I are disclosed.


IT 851449-69-9P 851449-70-2P 851449-71-3P
851449-72-4P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazacyclononene derivs. as inhibitors of renin)

RN 851449-69-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-(3-hydroxypropoxy)-3-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 851449-70-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-N-[(2-(3-hydroxypropoxy)-3-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851449-71-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-N-cyclopropyl-N-[(2-(2-hydroxyethoxy)-3-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)





RN 851449-72-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-N-[(2-(2-hydroxyethoxy)-3-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1059175 CAPLUS
DOCUMENT NUMBER: 142:38278
TITLE: Preparation of 3,9-diazabicyclo[3.3.1]nonene derivatives as inhibitors of parasite aspartic proteases
INVENTOR(S): Bur, Daniel; Fischli, Walter; Remen, Lubos; Richard-Bildstein, Sylvia; Weller, Thomas; Bossa, Christoph; Binkert, Christoph; Meyer, Solange
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 177 pp.
DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105762	A1	20041209	WO 2004-EP5065	20040512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, T, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			WO 2003-EP5661	A 20030530
OTHER SOURCE(S):			MARPAT 142:38278	
GI				



AB Pharmaceutical compns. for treating diseases demanding the inhibition of parasite aspartic proteases contain one or more compound(s) of the general formula (I) [X, W = N, CH; V = (CH₂)_r, A-(CH₂)_s, CH₂-A-(CH₂)_t, (CH₂)_s-A, (CH₂)₂-A-(CH₂)_u; A(CH₂)_v-B, (CH₂)₃-A-CH₂, A-CH₂CH₂-B-CH₂, CH₂-A-CH₂CH₂-B, (CH₂)₃-A-CH₂CH₂, (CH₂)₄-A-CH₂, A-CH₂CH₂-B-CH₂-CH₂, CH₂-A-CH₂-CH₂-B-CH₂, CH₂-A-(CH₂)₃-B, CH₂CH₂-A-CH₂CH₂-B (wherein A, B = O, S, SO, SO₂; r = 3-6; s = 2-5; t = 1-4; u = 1-3; v = 2-4); U = aryl, heteroaryl; T = CONR₁, (CH₂)_pOCO, (CH₂)_pN(R₁)CO, (CH₂)_pN(R₁)SO₂, COO (wherein R₁ = H, lower alkyl, alkenyl, or alkynyl, etc.; p = 1-4); Q = lower alkylene or alkenylene; W = H, cycloalkyl, aryl, heterocyclyl, heteroaryl; L = R₃, COR₃, COOR₃, CONR₂R₃, SO₂R₃, SO₂NR₂R₃, COCH(Aryl)₂ (wherein R₂ = H, lower alkyl or alkenyl, cycloalkyl, cycloalkyl-lower alkyl; R₃ = H, each (un)substituted lower alkyl or alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl-lower alkyl, aryl-lower alkyl, heteroaryl-lower alkyl, heterocyclyl-lower alkyl, aryloxy-lower alkyl, or heteroaryloxy-lower alkyl); m, n = 0 or 1], optically pure enantiomers, mixts. of enantiomers such as racemates, diastereomers, mixts. of diastereomers, diastereomeric racemates, mixts. of diastereomeric racemates, and the meso-form as well as pharmaceutically acceptable salts, solvent complexes and morphol. forms and suitable carrier materials. The pharmaceutical compns. are useful for the treatment or prevention of malaria or diseases caused by protozoal infection. The invention also concerns related aspects including processes for the preparation of the pharmaceutical compns. containing one or more of those compds. and especially their use as inhibitors of plasmeprin II. For example, compound (II) showed IC₅₀ of <10 nM against plasmeprin II.



CM 2


CRN 64-18-6
CMF C H2 O2

O=CH-OH

IT 625419-28-5P 625419-30-9P 625419-36-5P
625419-52-5P 625419-99-0P 625420-01-1P
625420-07-7P 625420-31-7P 625420-37-3P
625420-41-9P 625420-49-7P 625420-91-9P
625420-95-3P 625420-97-5P 625421-23-0P
625421-40-1P 625421-42-3P 625421-44-5P
625421-46-7P 625421-50-3P 625424-22-8P
625424-34-2P 625424-36-4P 625424-48-8P
625424-50-2P 625424-52-4P 625424-60-4P
625424-62-6P 625424-64-8P 625424-66-0P
625424-68-2P 625424-70-6P 625424-72-8P
625426-50-8P 625426-61-1P 625427-38-5P
625427-86-3P 625427-88-5P 625427-92-1P
625431-28-9P 625431-53-0P 625433-91-2P
807615-51-6P 807615-53-8P 807615-57-2P
807615-60-7P 807615-62-9P 807615-68-5P
807615-70-9P 807615-71-0P 807615-72-1P
807615-73-2P 807615-74-3P 807615-75-4P
807615-76-5P 807615-77-6P 807615-78-7P
807615-79-8P 807615-80-1P 807615-81-2P
807615-82-3P 807615-83-4P 807615-84-5P
807615-85-6P 807615-86-7P 807615-87-8P
807615-88-9P 807615-89-0P 807615-90-3P
807615-92-5P 807615-93-6P 807615-94-7P
807615-95-8P 807615-96-9P 807615-97-0P
807615-98-1P 807615-99-2P 807616-00-8P
807616-01-9P 807616-02-0P 807616-03-1P
807616-04-2P 807616-05-3P 807616-06-4P
807616-07-5P 807616-08-6P 807616-09-7P
807616-10-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


IT 807616-55-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 3,9-diazabicyclo[3.3.1]nonene derivs. as inhibitors of parasite aspartic proteases)
RN 807616-55-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-carboxylic acid, 6-[[[2-(chlorophenyl)methyl]cyclopropylamino]carbonyl]-7-[4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 625424-37-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3,9-diazabicyclo[3.3.1]nonene derivs. as inhibitors of parasite aspartic proteases)
RN 625424-37-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[[cyclopropyl]2-(2,3-difluorophenyl)ethyl]amino]carbonyl]-8-oxo-, monoformate.(9CI) (CA INDEX NAME)
CM 1
CRN 625424-36-4
CMF C39 H41 Br F3 N3 O5

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3,9-diazabicyclo[3.3.1]nonene derivs. as inhibitors of parasite aspartic proteases for treatment or prepn. of malaria diseases caused by protozoal infection)


RN 625419-28-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-[2-[3-(methoxyphenoxy)ethyl]phenyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625419-30-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-N-methyl-N-(2-phenylethyl)-7-[4-[2-[3-(trifluoromethoxy)phenoxy]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625419-36-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625419-52-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-[2-[3-(bromophenoxy)ethyl]phenyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625419-99-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(2-bromophenoxy)methyl]phenyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-01-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(1-fluorophenoxy)methyl]phenyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-07-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(4-(1,1-dimethylethyl)-4-methylphenoxy)methyl]phenyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-49-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(3,5-dimethylphenoxy)methyl]phenyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-91-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(3-(2-chlorophenoxy)propyl)phenyl]-N-[2-(2-chlorophenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625420-95-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(3-(2-chlorophenoxy)propyl)phenyl]-N-[(2-chlorophenyl)methyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 625420-31-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(2,5-dichlorophenoxy)methyl]phenyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-37-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(2-(3-chlorophenoxy)ethyl)phenyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-41-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(4-(1,1-dimethylethyl)-2-methylphenoxy)methyl]phenyl-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 625420-97-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(3-(2-chlorophenoxy)propyl)phenyl]-N-methyl-N-(3-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 625421-23-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(4-(3-(2-bromo-5-fluorophenoxy)propyl)phenyl)-N-cyclopropyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 625421-40-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[(4-(3-(2-bromo-5-fluorophenoxy)propyl)phenyl)-N-[2-(2-chlorophenyl)ethyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 625421-46-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide,
3-acetyl-7-[4-{3-(2-bromo-
5-fluorophenyl)propyl}phenyl]-N-cyclopropyl-N-[2-(2-methylphenyl)ethyl]-
(9CI) (CA INDEX NAME)




RN 625421-50-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide,
3-acetyl-7-[4-{3-(2-bromo-
5-fluorophenoxy)propyl}phenyl]-N-cyclopropyl-N-[[3-(
trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

O=C(O)CC(=O)N1CC2C(C1)C(=O)N(C2Cc3ccccc3)Cc4ccccc4CC5C6C(C5)C(=O)N(C6)Cc7cc(Cl)ccc7


RN 625424-36-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-{3-(2-bromo-5-fluorophenoxy)propyl}phenyl]-6-[(cyclopropyl[2-(2,3-difluorophenyl)ethyl]amino)carbonyl]-8-oxo- (9CI) (CA INDEX NAME)

O=C(O)CC(=O)N1CCc2c(c1)C(=O)N(C2Cc3ccccc3)C(=O)N(C4CC4)CCc5cc(F)ccc5

RN 625424-48-8 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[(cyclopropyl[(2-fluorophenyl)methyl]amino)carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-50-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-52-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[[2-(2,3-difluorophenyl)methyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)


RN 625424-64-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[2-(2,3-difluorophenyl)ethyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-66-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[2-(4-fluorophenyl)ethyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-68-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[2-(2-methylphenyl)ethyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-60-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[2-(phenylethyl)amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-62-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[[2-(2-chlorophenyl)ethyl]cyclopropylamino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-70-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[3,5-dimethoxyphenyl]methyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625424-72-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[2-(4-methylphenyl)ethyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625426-50-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625426-61-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl(phenylmethyl)amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625427-92-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-6-[[cyclopropyl[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625431-28-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-methyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 625431-53-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[(2-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625427-38-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-N-[(2-chlorophenyl)methyl]-N-ethyl-3-formyl- (9CI) (CA INDEX NAME)




RN 625427-86-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-6-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625427-88-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-6-[[[(2-chlorophenyl)methyl]ethylamino]carbonyl]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 625433-91-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[2-(2-bromo-5-fluorophenoxy)ethyl]phenyl]-6-[[methyl(2-phenylethyl)amino]carbonyl]-8-oxo- (9CI) (CA INDEX NAME)




RN 807615-51-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl(phenylmethyl)amino]carbonyl]-α,α-dimethyl-8-oxo- (9CI) (CA INDEX NAME)




RN 807615-53-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl[(2-methylphenyl)methyl]amino]carbonyl]-α,α-dimethyl-8-oxo- (9CI) (CA INDEX NAME)




RN 807615-57-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]- α,α -dimethyl-8-oxo- (9CI) (CA INDEX NAME)




RN 807615-60-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[[cyclopropyl[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]- α,α -dimethyl-8-oxo- (9CI) (CA INDEX NAME)



RN 807615-70-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 6-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]- α,α -dimethyl-8-oxo-7-[4-[3-(2,4,6-trifluorophenoxy)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 807615-71-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 6-[[[cyclopropyl[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-8-oxo-7-[4-[3-(2,4,6-trifluorophenoxy)propyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 807615-62-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-N-cyclopropyl-3-[[[(2R,4S)-4-hydroxy-2-pyrrolidinyl]carbonyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 807615-68-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 6-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]-8-oxo-7-[4-[3-(2,4,6-trifluorophenoxy)propyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 807615-72-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-N-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]-8-oxo-7-[4-[3-(2,4,6-trifluorophenoxy)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 807615-73-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 6-[[[(2-chlorophenyl)methyl]cyclopropylamino]carbonyl]-8-oxo-7-[4-[3-(2,4,6-trifluorophenoxy)propyl]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 807615-74-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide,
N-[(2-chlorophenyl)methyl]-
N-cyclopropyl-7-[4-[3-(2,4,6-trifluorophenoxy)propyl]phenyl]- (9CI) (CA
INDEX NAME)




RN 807615-75-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[2-(4-bromophenoxy)ethoxy]phenyl]-6-[[cyclopropyl[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]- α,α -dimethyl-8-oxo- (9CI) (CA INDEX NAME)




RN 807615-76-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[2-(2-chloro-4,5-dimethylphenoxy)ethoxy]phenyl]-6-[[cyclopropyl[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]- α,α -dimethyl-8-oxo- (9CI) (CA INDEX NAME)



RN 807615-80-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-butyl-7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-3-formyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 807615-81-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[3-(2-chlorophenyl)propyl]-3-formyl-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-82-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[(3,4-difluorophenyl)methyl]-3-formyl-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 807615-77-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[(2-(4-fluorophenyl)ethyl)-3-formyl-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-78-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[(3,4-dichlorophenyl)methyl]-3-formyl-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-79-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide,
N-[(4-bromophenyl)methyl]-
7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-3-formyl-N-methyl- (9CI) (CA
INDEX NAME)


L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 807615-83-4 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[(2,4-dichlorophenyl)methyl]-3-formyl-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-84-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-N-[(4-chlorophenyl)methyl]-3-formyl-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-85-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[3-(2-chlorophenoxy)propyl]phenyl]-3-formyl-N-methyl-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)







RN 807615-86-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 807615-87-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 807615-88-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 807615-93-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(2-bromophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 807615-94-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(2,4-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 807615-95-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(5-phenylpentyl)- (9CI) (CA INDEX NAME)




RN 807615-89-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(3,4-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 807615-90-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-[(3-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-92-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-[(3,4-difluorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-96-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-methyl-N-[(3-(2-methylphenyl)propyl)- (9CI) (CA INDEX NAME)




RN 807615-97-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-[(2-phenylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 807615-98-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-[4-{3-(2-chlorophenoxy)propyl}phenyl]-N-[(2,4-dichlorophenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 807615-99-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 3-acetyl-7-([4-[3-(2-chlorophenoxy)propyl]phenyl]-N-methyl-N-[2-(2,4,6-trimethylphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 807616-00-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[(cyclopropyl(2-(2,3-difluorophenyl)ethyl)amino)carbonyl]-α,α-dimethyl-δ-oxo- (9CI) (CA INDEX NAME)



RN 807616-01-9 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-




RN 807616-04-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[(cyclopropyl(2-(4-fluorophenyl)ethyl)amino)carbonyl]-α,α-dimethyl-δ-oxo- (9CI) (CA INDEX NAME)




RN 807616-05-3 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[(cyclopropyl(2-(4-methylphenyl)ethyl)amino)carbonyl]-α,α-dimethyl-δ-oxo- (9CI) (CA INDEX NAME)


fluorophenoxy)propyl]phenyl]-6-[[[2-(2-chlorophenyl)ethyl]cyclopropylamino]carbonyl]-γ,γ-dimethyl-δ-oxo- (9CI) (CA INDEX NAME)




RN 807616-02-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl(2-(2-methylphenyl)ethyl)amino]carbonyl]-γ,γ-dimethyl-δ-oxo- (9CI) (CA INDEX NAME)



RN 807616-03-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-3-pentanoic acid, 7-[4-[3-(2-bromo-5-fluorophenoxy)propyl]phenyl]-6-[[cyclopropyl(2-phenylethyl)amino]carbonyl]-α,α-dimethyl-δ-oxo- (9CI) (CA INDEX NAME)




RN 807616-06-4 CAPLUS
CN Carbamic acid, [5-(7-[4-[2-(2-bromo-4-fluorophenoxy)ethyl]phenyl]-6-[[methyl(2-phenylethyl)amino]carbonyl]-3,9-diazabicyclo[3.3.1]non-6-en-3-yl]-1,5-dioxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


RN 807616-07-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[7-[4-[2-(2-bromo-4-fluorophenoxy)ethyl]phenyl]-6-[[methyl(2-phenylethyl)amino]carbonyl]-3,9-diazabicyclo[3.3.1]non-6-en-3-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 807616-08-6 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-(2-bromo-5-fluorophenoxy)ethyl]phenyl]-3-(3-hydroxy-1-oxobutyl)-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 807616-09-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-(2-bromo-5-fluorophenoxy)ethyl]phenyl]-N-methyl-N-(2-phenylethyl)-3-(1H-tetrazol-1-ylacetyl)- (9CI) (CA INDEX NAME)



RN 807616-10-0 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, 7-[4-[2-(2-bromo-5-fluorophenoxy)ethyl]phenyl]-3-(hydroxyacetyl)-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)


ACCESSION NUMBER: 2004:965250 CAPLUS
DOCUMENT NUMBER: 141:395706
TITLE: Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
INVENTOR(S): Bezencon, Olivier; Bur, Daniel; Fischli, Walter; Remen, Lubos; Richard-Bildstein, Sylvia; Weller, Thomas
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096804	A1	20041111	WO 2004-EP4373	20040426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004234040	A1	20041111	AU 2004-234040	20040426
CA 2521951	A1	20041111	CA 2004-2521951	20040426
EP 1622906	A1	20060208	EP 2004-729415	20040426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1780836	A	20060531	CN 2004-80011240	20040426
JP 2006524656	T	20061102	JP 2006-505262	20040426
US 2006217371	A1	20060928	US 2005-554443	20051025
PRIORITY APPLN. INFO.:			WO 2003-EP4393	A 20030428
			WO 2003-EP304393	A 20030428
			WO 2004-EP4373	W 20040426

OTHER SOURCE(S): MARPAT 141:395706
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 3,9-Diazabicyclo[3.3.1]nonene derivs. I (Z, Y, X, W = N, or -CH; V = alkyl, alkoxy, sulfide, sulfoxo, sulfate; U = aryl, heteroaryl; T = amide, sulfamide, ester; Q = lower alkylene or alkenylene; L = H, alkyl, alkene, aryl, heteroaryl, alkoxy, aryloxy, CN, ester, amide, sulfate, sulfamide, etc.; M = H, cycloalkyl, aryl, heterocycle, heteroaryl) were prepared as renin inhibitors for the treatment of cardiovascular and renal diseases. Thus, II was treated with 2-chlorophenol, TMD, and tri-Bu phosphine to give the aryl ether which was deprotected using THF/AcOH to give III.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


IT 790696-38-7P 790696-39-8P 790696-40-1P
790696-41-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
inhibitors
for the treatment of cardiovascular disease, renal diseases, and other related conditions)
RN 790696-38-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 790696-39-8 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[4-(2-fluoro-4-(trifluoromethyl)phenoxy)butoxy]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 790696-40-1 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-7-[4-[4-(2,6-dichloro-4-methylphenoxy)butoxy]phenyl]-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 790696-41-2 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide,
7-[4-(2-chloro-6-fluoro-4-methylphenoxy)butoxyphenyl]-N-cyclopropyl-N-[(3-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2004:964985 CAPLUS
DOCUMENT NUMBER: 141:410959
TITLE: Preparation of
7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene
derivatives and their use as renin inhibitors in the
treatment of hypertension, cardiovascular or renal
diseases
INVENTOR(S): Bezencon, Olivier; Bur, Daniel; Fischli, Walter;
Remen, Lubos; Richard-Bildstein, Sylvia; Weller,
Thomas; Sifferlen, Thierry
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096116	A2	20041111	WO 2004-EP4372	20040426
WO 2004096116	A3	20050324		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004233577	A1	20041111	AU 2004-233577	20040426
CA 2521898	A1	20041111	CA 2004-2521898	20040426
EP 1622564	A2	20060208	EP 2004-729414	20040426
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004009882	A	20060523	BR 2004-9882	20040426
CN 1780838	A	20060531	CN 2004-8001650	20040426
JP 2006525259	T	20061109	JP 2006-505261	20040426
US 2006223795	A1	20061005	US 2006-555382	20051102
PRIORITY APPLN. INFO.:			WO 2003-EP304622	A 20030502
			WO 2004-EP4372	W 20040426

OTHER SOURCE(S): CASREACT 141:410959; MARPAT 141:410959
GI



AB The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivs. of formula (I) (wherein W = six-membered non benzofused, Ph or heterocyclic ring substituted in the meta or para positions; V = OCH₂CH(OMe)CH₂O, OCH₂CH(Me)CH₂O, OCH₂CH(CF₃)CH₂O, OCH₂CH(Me)CH₂O, OCH₂CH(OMe)CH₂O, OCH₂CH(CH₂CH₂)₂O, O(CH₂CH₂)₂CH₂O; U = aryl, heteroaryl; T = CONR₁, (CH₂)_pOCO, (CH₂)_pN(R₁)CO, (CH₂)_pN(R₁)SO₂, or CO₂; Q = lower alkylene, or alkenylene; M = H, cycloalkyl, aryl, heterocyclyl, heteroaryl; L = R₃, COR₃, CO₂R₃, CONR₂R₃, SO₂R₃, SO₂NR₂R₃, COCH(Aryl)₂;

R1 = H; lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, cycloalkyl-lower alkyl; R2 = H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl; R3 = H, lower alkyl, lower alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl-lower alkyl, aryl-lower alkyl, heteroaryl-lower alkyl, heterocyclyl-lower alkyl, aryloxy-lower alkyl, heteroaryloxy-lower alkyl, where by these groups may be unsubstituted or mono, di- or trisubstituted; m, n = 0 or 1, with the proviso that in case m is 1, n is 0, or vice versa; p = an integer of 1-4; k = an integer of 0-1 and optically pure enantiomers, mixts. of enantiomers such as racemates, diastereomers, mixts. of diastereomers, diastereomeric racemates, etc. and pharmaceutically acceptable salts, solvates, and morphol. forms were prepared. Also provided are pharmaceutical compns. containing the compds. as the active ingredients for treatment or prophylaxis

of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases, hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS. Thus, (1R,5S)-7-[4-[(2S)-2-methyl-3-

(2,3,6-trifluorophenoxy)propoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl(2,3-dichlorobenzyl)amide and


(1S,5R)-7-[4-[(2S)-2-methyl-3-(2,3,6-trifluorophenoxy)propoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl(2,3-dichlorobenzyl)amide were prepared starting from (-)-Me D-β-hydroxyisobutyrate.

IT 791065-37-7P 793709-22-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
[prepn. of 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivs. and their use as renin inhibitors in treatment of hypertension, cardiovascular or renal diseases)


RN 791065-37-7 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(2S)-2-methyl-3-(2,3,6-trifluorophenoxy)propoxy]phenyl]- (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 793709-22-5 CAPLUS
CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[4-[(2S)-2-methyl-3-(2,3,6-trifluorophenoxy)propoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 791065-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivs. and their use as renin inhibitors in treatment of hypertension, cardiovascular or

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 renal diseases)
 RN 791065-38-8 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-cyclopropyl-N-[(2,3-dichlorophenyl)methyl]-7-[(4-[(2S)-2-methyl-3-(2,3,6-trifluorophenoxy)propoxy]phenyl)-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:395949 CAPLUS
 DOCUMENT NUMBER: 139:395949
 TITLE: Preparation of 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
 INVENTOR(S): Bezencon, Olivier; Bur, Daniel; Fischli, Walter; Remen, Lubos; Richard-Bildstein, Sylvia; Weber, Hans-Peter; Weller, Thomas
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
 SOURCE: PCT Int. Appl., 514 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093267	A1	20031113	WO 2003-EP3721	20030408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483241	A1	20031113	CA 2003-2483241	20030408
AU 2003233963	A1	20031117	AU 2003-233963	20030408
EP 1501830	A1	20050202	EP 2003-727287	20030408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009498	A	20050215	BR 2003-9498	20030408
CH 1649870	A	20050803	CN 2003-809766	20030408
US 2005176700	A1	20050818	US 2003-513103	20030408
JP 2005527602	T	20050915	JP 2004-501406	20030408
NZ 536750	A	20070223	NZ 2003-536750	20030408
IN 2004CN02435	A	20070302	IN 2004-CN2435	20041027
NO 2004005042	A	20041119	NO 2004-5042	20041119
PRIORITY APPL. INFO.:				WO 2002-EP4705 A 20020429
				WO 2003-EP3721 W 20030408

OTHER SOURCE(S): MARPAT 139:395949
 GI


L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivs. of formula (I) (wherein X, W = N, CH; V = (CH₂)_x, A-(CH₂)_s, CH₂-A-(CH₂)_t, (CH₂)₂-A-(CH₂)_u, A-(CH₂)_v-B, (CH₂)₃-A-CH₂, A-CH₂CH₂-B-CH₂, CH₂-A-CH₂CH₂-B, (CH₂)₃-A-CH₂CH₂, (CH₂)₄-A-CH₂, A-CH₂CH₂-B-CH₂CH₂, CH₂-A-CH₂CH₂-B-CH₂, CH₂-A-(CH₂)₃-B, CH₂CH₂-A-CH₂CH₂-B; A, B = O, S, SO, SO₂; U aryl, heteroaryl; T = CONR₁, (CH₂)_pOCO, (CH₂)_pN(R₁)CO, (CH₂)_pN(R₁)SO₂, or CO₂; Q = lower alkylene, or alkenylene; M = H, cycloalkyl, aryl, heterocyclyl, heteroaryl; L = R₃, COR₃, CO₂R₃, CONR₂R₃, SO₂R₃, SO₂NR₂R₃, COCH(Aryl)₂; R₁ = H; lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, cycloalkyl-lower alkyl; R₂ = H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl; R₃ = H, lower alkyl, lower alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl-lower alkyl, aryl-lower alkyl, heteroaryl-lower alkyl, heterocyclyl-lower alkyl, aryloxy-lower alkyl, heteroaryloxy-lower alkyl, where by these groups may be unsubstituted or mono, di- or trisubstituted; m, n = 0 or 1, with the proviso that in case m is 1, n is 0, or vice versa; p, t = an integer of 1-4; r = an integer of 3-6; s = an integer 2-5; u = an integer 1-3; v = an integer of 2-4) and optically pure enantiomers, mixts. of enantiomers such as racemates, diastereomers, mixts. of diastereomers, diastereomeric racemates, etc. and pharmaceutically acceptable salts, solvates, and morphol. forms. Also provided are pharmaceutical compns. containing the compds. as the active ingredients for treatment or prophylaxis of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases, hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS. The IC₅₀-values of all compds. tested against recombinant human renin were below 100 nM.
 IT 625433-85-4P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivs. as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 625433-85-4 CAPLUS
 CN 3,9-Diazabicyclo[3.3.1]non-6-ene-6-carboxamide, N-[(2-chlorophenyl)methyl]-N-cyclopropyl-3-[(2S,4R)-4-hydroxy-2-pyrrolidinyl]carbonyl]-7-[(4-[(2S,3,6-trifluorophenoxy)propoxy]phenyl)-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 625418-50-0P 625418-51-1P 625418-52-2P
 625418-53-3P 625418-54-4P 625418-55-5P
 625418-56-6P 625418-57-7P 625418-58-8P
 625418-59-9P 625418-62-4P 625418-63-5P
 625418-64-6P 625418-65-7P 625418-66-8P
 625418-67-9P 625418-70-4P 625418-71-5P
 625418-72-6P 625418-73-7P 625418-75-9P
 625418-76-0P 625418-78-2P 625418-79-3P
 625418-81-7P 625418-82-8P 625418-84-0P
 625418-85-1P 625418-87-3P 625418-88-4P
 625418-89-5P 625418-90-8P 625418-91-9P
 625418-92-0P 625418-93-1P 625418-94-2P
 625418-96-4P 625418-97-5P 625418-99-7P
 625419-03-6P 625419-05-8P 625419-07-0P
 625419-09-2P 625419-11-6P 625419-13-8P
 625419-15-0P 625419-17-2P 625419-19-4P
 625419-21-8P 625419-23-0P 625419-25-2P
 625419-26-3P 625419-27-4P 625419-29-6P
 625419-31-0P 625419-33-2P 625419-34-3P
 625419-35-4P 625419-37-6P 625419-39-8P
 625419-41-2P 625419-42-3P 625419-43-4P
 625419-45-6P 625419-47-8P 625419-49-0P
 625419-51-4P 625419-53-6P 625419-55-8P
 625419-57-0P 625419-60-5P 625419-62-7P
 625419-63-8P 625419-65-0P 625419-67-2P
 625419-69-4P 625419-70-7P 625419-72-9P
 625419-74-1P 625419-76-3P 625419-78-5P
 625419-80-9P 625419-82-1P 625419-84-3P
 625419-86-5P 625419-88-7P 625419-90-1P
 625419-91-2P 625419-92-3P 625419-93-4P
 625419-94-5P 625419-96-7P 625419-98-9P
 625420-00-0P 625420-02-2P 625420-04-4P
 625420-06-6P 625420-07-7P 625420-08-8P
 625420-10-2P 625420-12-4P 625420-13-5P

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


625420-14-6P 625420-15-7P 625420-16-8P
625420-18-0P 625420-19-1P 625420-20-4P
625420-22-6P 625420-24-8P 625420-26-0P
625420-28-2P 625420-30-6P 625420-32-8P
625420-34-0P 625420-36-2P 625420-38-4P
625420-40-8P 625420-42-0P 625420-44-2P
625420-46-4P 625420-48-6P 625420-50-0P
625420-52-2P 625420-53-3P 625420-54-4P
625420-55-5P 625420-56-6P 625420-57-7P
625420-58-8P 625420-60-2P 625420-61-3P
625420-62-4P 625420-64-6P 625420-66-8P
625420-68-0P 625420-70-4P 625420-72-6P
625420-74-8P 625420-76-0P 625420-78-2P
625420-80-6P 625420-82-8P 625420-84-0P
625420-86-2P 625420-88-4P 625420-90-8P
625420-92-0P 625420-94-2P 625420-95-3P
625420-96-4P 625420-98-6P 625421-00-3P
625421-02-5P 625421-04-7P 625421-06-9P
625421-08-1P 625421-10-3P 625421-12-7P
625421-14-9P 625421-16-1P 625421-17-2P
625421-19-4P 625421-21-8P 625421-24-1P
625421-27-4P 625421-29-6P 625421-31-0P
625421-33-2P 625421-35-4P 625421-37-6P
625421-39-8P 625421-41-2P 625421-43-4P
625421-45-6P 625421-47-8P 625421-49-0P
625421-51-4P 625421-53-6P 625421-54-7P
625421-55-8P 625421-56-9P 625421-65-0P
625421-66-1P 625421-67-2P 625421-68-3P
625421-70-7P 625421-71-8P 625421-72-9P
625421-73-0P 625421-74-1P 625421-75-2P
625421-76-3P 625421-77-4P 625421-78-5P
625421-79-6P 625421-80-9P 625421-81-0P
625421-82-1P 625421-84-3P 625421-86-5P
625421-88-7P 625421-90-1P 625421-91-2P
625421-92-3P 625421-93-4P 625421-94-5P
625421-96-7P 625421-98-9P 625422-00-6P
625422-01-7P 625422-02-8P 625422-04-0P
625422-06-2P 625422-08-4P 625422-10-8P
625422-12-0P 625422-14-2P 625422-16-4P
625422-18-6P 625422-20-0P 625422-22-2P
625422-23-3P 625422-25-5P 625422-26-6P
625422-28-8P 625422-29-9P 625422-31-3P
625422-32-4P 625422-34-6P 625422-35-7P
625422-37-9P 625422-38-0P 625422-40-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivs. as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases)

RN 625418-50-0 CAPLUS
CN Benzeneacetic acid, 2-methoxy-, [3-[(4-chlorophenyl)acetyl]-7-[4-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-en-6-yl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 625418-51-1 CAPLUS
CN Benzeneacetic acid, 2-methoxy-, [3-[(4-chlorophenyl)acetyl]-7-[4-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3,9-diazabicyclo[3.3.1]non-6-en-6-yl)methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625418-50-0

CMF C42 H45 Cl N2 O7



CM 2


CRN 76-05-1

CMF C2 H F3 O2

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 625418-52-2 CAPLUS
CN Benzeneacetic acid, 2-methoxy-, [7-[4-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-(2-quinoxalinylylcarbonyl)-3,9-diazabicyclo[3.3.1]non-6-en-6-yl)methyl ester (9CI) (CA INDEX NAME)




RN 625418-53-3 CAPLUS
CN Benzeneacetic acid, 2-methoxy-, [7-[4-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-(2-quinoxalinylylcarbonyl)-3,9-diazabicyclo[3.3.1]non-6-en-6-yl)methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 625418-52-2

CMF C43 H44 N4 O7

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 625418-54-4 CAPLUS
CN Benzeneacetic acid, 2-methoxy-, [7-[4-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-[(phenylmethyl)sulfonyl]-3,9-diazabicyclo[3.3.1]non-6-en-6-yl)methyl ester (9CI) (CA INDEX NAME)



RN 625418-55-5 CAPLUS
CN Benzeneacetic acid, 2-methoxy-, [7-[4-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-[(phenylmethyl)sulfonyl]-3,9-diazabicyclo[3.3.1]non-6-en-6-yl)methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)